Copolymer Effects on Microglia and T Cells in the Central Nervous System of Humanized Mice
Overview
Authors
Affiliations
The random amino acid copolymers FYAK and VWAK ameliorate EAE in a humanized mouse model expressing both a human transgenic myelin basic protein (MBP)85-99-specific T cell receptor and HLA-DR2. Here we show that microglia isolated from the central nervous system (CNS) of humanized mice with EAE induced by MBP85-99 and treated with these copolymers had reduced expression of HLA-DR, and thus reduced capacity to present MBP85-99 and activate transgenic T cells. In vitro microglia up-regulated empty HLA-DR2 upon activation with GM-CSF with or without LPS or IFN-gamma, but not with IL-4 or IL-10. Correspondingly, gene chip arrays showed that the CNS of untreated and YFAK-treated mice differentially expressed pro- and anti-inflammatory molecules during MBP85-99-induced EAE. Interestingly, microglia expressed the full-length gammabeta and alphabeta subunits of the tetrameric adaptor protein complexes AP-1 and AP-2 respectively, but after treatment with GM-CSF these complexes were cleaved, as had been found in immature dendritic cells derived from bone marrow. Strikingly, in vivo the perivascular lymphocyte infiltration seen in untreated mice immunized with MBP85-99 was composed of equal numbers of hVbeta2+ MPB85-99-specific transgenic and hVbeta2- endogenous T cells, while the much smaller infiltration seen after treatment with YFAK was composed predominantly of hVbeta2- endogenous T cells.
HLA-transgenic mouse models to study autoimmune central nervous system diseases.
Pressley K, Schwegman L, Montes De Oca Arena M, Chase Huizar C, Zamvil S, Forsthuber T Autoimmunity. 2024; 57(1):2387414.
PMID: 39167553 PMC: 11470778. DOI: 10.1080/08916934.2024.2387414.
Biomaterial strategies for generating therapeutic immune responses.
Kelly S, Shores L, Votaw N, Collier J Adv Drug Deliv Rev. 2017; 114:3-18.
PMID: 28455189 PMC: 5606982. DOI: 10.1016/j.addr.2017.04.009.
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
Tyler A, Mendoza J, Firan M, Karandikar N PLoS One. 2013; 8(6):e66772.
PMID: 23805274 PMC: 3689655. DOI: 10.1371/journal.pone.0066772.
Kawamoto N, Ohnishi H, Kondo N, Strominger J Int Immunol. 2012; 25(1):53-65.
PMID: 22968996 PMC: 3619970. DOI: 10.1093/intimm/dxs087.
Emerson M, Gallagher R, Marquis J, Levine S Comp Med. 2009; 59(2):112-28.
PMID: 19389303 PMC: 2703151.